La nostra esperienza nel trattamento della pubertà precoce

Gli Autori riferiscono i risultati ottenuti in 54 bambine affette da pubertà precoce idiopatica ed in 10 bambine con pubertà anticipata utilizzando gli analoghi del GnRh. I loro risultati sono simili a quanto riportato in letteratura e dimostrano che la terapia è più efficace sulla pubertà precoce rispetto a quella anticipata ed è in genere ben tollerata. Gli Autori insistono sulla necessità di selezionare accuratamente le piccole pazienti prima di cominciare qualsiasi trattamento e ritengono che l'efficacia della terapia possa essere valutata sfruttando parametri clinici

Informazione contraccettiva e adolescenza: risultati di una indagine condotta nelle scuole superiori della città di Messina

Gli Autori riportano i risultati di un’indagine conoscitiva sui metodi contraccettivi effettuata in alcune scuole superiori della città di Messina. Gli adolescenti intervistati hanno dimostrato una scarsa conoscenza dei metodi contraccettivi e, nonostante una discreta percentuale di essi dichiari di aver avuto rapporti sessuali, solo pochi praticano la contraccezione. Gli Autori ritengono che gli interventi di educazione sessuale vadano implementati nelle scuole e debbano coinvolgere anche le scuole medie inferiori

PRIMO PROTOCOLLO PER NEUROBLASTOMA AD ALTO RISCHIO siop EUROPE NEUROBLASTOMA. REPORT AD INTERIM DELLA CASISTICA ITALIANA.

Risultati del protocollo SIOP Europa sul neuroblastoma ad alto rischi

Preliminary data revealing efficacy of Streptococcus salivarius K12 (SSK12) in Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adenitis (PFAPA) syndrome: a multicenter study from the AIDA Network PFAPA syndrome registry

Objective: To evaluate the potential role of Streptococcus salivarius K12 (SSK12) in controlling febrile flares in patients with Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adenitis (PFAPA) syndrome. Further aims were to assess the impact of SSK12 on (i) flare duration, (ii) variation in the degree of the highest body temperature during flares, (iii) steroid-sparing effect, and (iv) change of PFAPA accompanying symptoms before and after SSK12 introduction. Patients and methods: The medical charts from 85 pediatric patients with PFAPA syndrome (49 males and 36 females) enrolled in the AIDA registry and treated with SSK12 for a median period of 6.00±7.00 months in the period between September 2017 and May 2022 were examined. Children recruited had a median time of disease duration of 19.00±28.00 months. Results: The number of febrile flares significantly decreased comparing the 12 months before [median (IQR), 13.00 (6.00)] and after SSK12 initiation [median (IQR), 5.50 (8.00), p<0.001]. The duration of fever was significantly reduced from 4.00 (2.00) days to 2.00 (2.00) days [p<0.001]. Similarly, the highest temperature in °C was found significantly lower in the last follow-up assessment [median (IQR), 39.00 (1.00)] compared to the period prior to SSK12 start [median (IQR), 40.00 (1.00), p<0.001]. Steroid load (mg/year) of betamethasone (or any equivalent steroid) significantly decreased between 12 months before treatment with SSK12 [median (IQR), 5.00 (8.00) mg/year] and the last follow-up visit [median (IQR), 2.00 (4.00) mg/year, p<0.001]. The number of patients experiencing symptoms including pharyngitis/tonsillitis (p<0.001), oral aphthae (p<0.001) and cervical lymphadenopathy (p<0.001) significantly decreased following SSK12. Conclusion: SSK12 prophylaxis given for at least 6.00±7.00 months was found to reduce febrile flares of PFAPA syndrome: in particular, it halved the total number per year of fever flares, shortened the duration of the single febrile episode, lowered body temperature by 1°C in the febrile flare, provided a steroid-sparing effect, and significantly reduced the accompanying symptoms related to the syndrome

Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials?

Introduction: SIOPEN INES protocol yielded excellent 5-year survival rates for MYCN-non-amplified metastatic\uc2\ua0neuroblastoma. Patients deemed ineligible due to lack or delay of MYCN status or late registration were treated, but not included in the study. Our goal was to analyse survival at 10\uc2\ua0years among the whole population. Materials and methods: Italian and Spanish metastatic INES patients\ue2\u80\u99 data are reported. SPSS 20.0 was used for statistical analysis. Results: Among 98 infants, 27 had events and 19 died, while 79 were disease free. Five- and 10-year event-free survival (EFS) were 73 and 70\uc2\ua0%, and overall survival (OS) was 81 and 74\uc2\ua0%, respectively. MYCN status was significant for EFS, but not for OS in multivariate analysis. Conclusions: The survival rates of patients who complied with all the inclusion criteria for INES trials are higher compared to those that included also not registered patients. Five-year EFS and OS for INES 99.2 were 87.8 and 95.7\uc2\ua0%, while our stage 4s population obtained 78 and 87\uc2\ua0%. Concerning 99.3, 5-year EFS and OS were 86.7 and 95.6\uc2\ua0%, while for stage 4 we registered 61 and 68\uc2\ua0%. MYCN amplification had a strong impact on prognosis and therefore we consider it unacceptable that many patients were not studied for MYCN and probably inadequately treated. Ten-year survival rates were shown to decrease: EFS from 73 to 70\uc2\ua0% and OS from 81 to 74\uc2\ua0%, indicating a risk of late events, particularly in stage 4s. Population-based registries like European ENCCA WP 11-task 11 will possibly clarify these data

Borrowers and innovators in the history of printing Sacrobosco: The case of the “in-octavo tradition

International audienc